Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting

AI SummaryClose X

Faron Pharmaceuticals Ltd announced that its extraordinary general meeting approved the Board of Directors' proposal to authorize a rights offering of up to 80,000,000 new shares, valid until June 30, 2026, with unsubscribed shares potentially offered to other shareholders or third parties. This authorization does not revoke previous share issuance authorities. The company is developing bexmarilimab, an immunotherapy targeting Clever-1 for hematological cancers, currently in a Phase I/II clinical trial for acute myeloid leukemia and myelodysplastic syndrome.

Disclaimer*

UK 100

Latest directors dealings